Related Experiment Videos
Surrogate end points for pulmonary arterial hypertension
Steven M Kawut1, Harold I Palevsky
1Lung Transplant Program, Division of Pulmonary, Allergy, and Critical Care Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA. sk2097@columbia.edu
American Heart Journal
|October 2, 2004
Summary
Identifying reliable surrogate endpoints is crucial for effective pulmonary arterial hypertension (PAH) clinical trials. Hemodynamic measures show the most promise for assessing PAH therapies and improving patient care.
Area of Science:
- Cardiology
- Pulmonology
- Clinical Trials
Background:
- Pulmonary arterial hypertension (PAH) involves high pulmonary vascular resistance and right heart failure.
- Effective PAH therapies have emerged from recent research and clinical trials.
- Current trials rely on surrogate endpoints, but their validity in PAH is uncertain.
Purpose of the Study:
- To evaluate the reliability and validity of potential surrogate endpoints for pulmonary arterial hypertension (PAH) clinical trials.
- To guide the selection of appropriate endpoints for future PAH research and clinical practice.
Main Methods:
- Review of existing data on hemodynamic, echocardiographic, neurohormone, and exercise measures as surrogate endpoints.
- Analysis of the strengths and weaknesses of each proposed metric for PAH studies.
Main Results:
- Hemodynamic measures demonstrate the strongest evidence for use as surrogate endpoints in PAH.
- Functional assessments, such as the 6-minute walk test, also show potential clinical relevance.
- No single surrogate endpoint is definitively validated, highlighting the need for further research.
Conclusions:
- Further validation studies are essential to confirm the reliability of promising surrogate endpoints in pulmonary arterial hypertension.
- Validated endpoints will enhance the design of clinical trials and improve patient management for PAH.